Stay updated on Pembrolizumab Combo in Resectable NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The clinical trial is now listed as completed and no longer seeking participants, with its completion date recorded as actual. The record also reflects an updated posting date and verification date.
    Difference
    0.2%
    Check dated 2026-11-21T10:26:22.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The clinical trial record for the pembrolizumab and chemotherapy study in resectable non-small cell lung cancer is available, with its study design, eligibility criteria, outcomes, locations, publications, and supporting documents.
    Difference
    100%
    Check dated 2026-11-07T11:09:04.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.2 to v3.8.0. The study page remains inaccessible and shows a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T10:00:16.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T10:57:30.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The footer now displays ClinicalTrials.gov revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-17T12:59:11.000Z thumbnail image
  7. Check
    43 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1; the study record still displays a 403 error.
    Difference
    0.2%
    Check dated 2026-10-10T12:34:27.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Resectable NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.